Solasia Pharma KK (JP:4597) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Solasia Pharma K.K. is advancing negotiations with several Chinese pharmaceutical companies for the out-licensing of its drug DARVIAS (SP-02) in China, with an updated expectation to conclude an agreement by the end of December 2024. The delay follows a recent confirmation from Chinese authorities regarding clinical trial designs for DARVIAS’s New Drug Application (NDA) in China. This revised timeline is not anticipated to affect the company’s consolidated financial forecast for the fiscal year 2024.
For further insights into JP:4597 stock, check out TipRanks’ Stock Analysis page.